• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer

byMinjee Kim
May 18, 2022
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Patients who underwent segmentectomy reported a significantly greater 5-year overall survival than those who underwent lobectomy (94.3% vs. 91.1%).

2. Median reduction in forced expiratory volume in one second (FEV1) was greater in the lobectomy group (12.0%) compared to segmentectomy (8.5%).

Evidence Rating Level: 1 (Excellent)

Study Rundown: Surgical resection is recommended as the standard of treatment for early-stage, operative lung cancer. Lobectomy, or the surgical removal of a lobe, has been the preferred surgical modality. However, smaller tumors located in the peripheries, a less invasive option may be beneficial for long-term survival. Alternatives, such as sublobar resection or segmentectomy, can be used, although evidence around long-term prognosis is unclear. This trial aimed to compare the long-term prognosis of segmentectomy versus lobectomy among patients with primary non-small cell lung cancer (NSCLC). The primary outcome was overall survival at 5 years post-surgery, while key secondary outcomes included 5-year relapse-free survival, frequency of adverse events, length of hospital stay, and pulmonary function assessment. According to study results, segmentectomy was associated with greater overall survival and decreased all-cause mortality compared to lobectomy. There were no differences in total relapse rates between groups. This study was strengthened by a large sample size and included patients with multiple comorbidities, thus adding to validity of findings.

Click to read the study in The Lancet

Relevant Reading: Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

RELATED REPORTS

Sinoatrial node radiation associated with the development of atrial fibrillation and mortality in lung cancer

#VisualAbstract: Adjuvant pembrolizumab increased disease-free survival in completely resected, PD-L1 unselected non-small-cell lung cancer patients

The RAPTURE trial: Radiofrequency ablation effective and safe in lung cancer [Classics Series]

In-depth [randomized-controlled trial]: Between Aug 10, 2009, and Oct 21, 2014, 1319 patients were enrolled across 70 institutions in Japan. Included were those aged ≥ 20 years with an Eastern Cooperative Oncology Group (ECOG) score of 0-1, and stage IA primary NSCLC. Altogether, 1106 patients (554 in lobectomy and 552 in segmentectomy) were included in the analysis. The primary outcome of 5-year survival was greater in the segmentectomy group (94.3%, 95% confidence interval [CI] 92.1-96.0) than in the lobectomy group (91.1%, 95% CI 88.4-93.2). The 5-year relapse-free survival was comparable in both groups (88.0%, 95% CI 85.0-90.4 for segmentectomy vs. 87.9%, 95% CI 84.8-90.3 for lobectomy; hazard ratio [HR] 0.998, 95% CI 0.735-1.323, p=0.9889). Segmentectomy was associated with a lower risk of all-cause mortality compared to lobectomy (47% vs. 63%). There was a significant difference in median reductions in FEV1 seen in patients randomized to lobectomy (12.0% at 12 months) compared to segmentectomy (8.5% at 12 months; p<0.0001). Findings from this study suggest that segmentectomy is superior to lobectomy among patients with early, stage IA, primary, non-invasive NSCLC.

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: FEV1lobectomylunglung cancerlung cancer treatmentnon-small cell lung cancernsclcsegmentectomy
Previous Post

Several factors influence health programs conducted in the African American Church

Next Post

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer

RelatedReports

Patient Basics: Radiation Therapy
Oncology

Sinoatrial node radiation associated with the development of atrial fibrillation and mortality in lung cancer

October 3, 2022
#VisualAbstract: Adjuvant pembrolizumab increased disease-free survival in completely resected, PD-L1 unselected non-small-cell lung cancer patients
StudyGraphics

#VisualAbstract: Adjuvant pembrolizumab increased disease-free survival in completely resected, PD-L1 unselected non-small-cell lung cancer patients

September 28, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Hematology/Oncology Classics

The RAPTURE trial: Radiofrequency ablation effective and safe in lung cancer [Classics Series]

July 1, 2022
Interstitial lung abnormalities linked to greater risk of all-cause mortality
Chronic Disease

Phosphodiesterase 4 inhibitor BI 1015550 preserves lung function in pulmonary fibrosis patients

June 18, 2022
Next Post
#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer

Caplacizumab may induce faster resolution of a thrombotic thrombocytopenic purpura episode

Oral methylprednisolone may reduce risk of progressive renal failure in patients with IgA nephropathy: TESTING Trial

Gardasil vaccine demonstrates immunogenic response at 10-year follow-up

Long-acting cabotegravir significantly decreases incidence of HIV compared to daily oral tenofovir

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
  • #VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension
  • High-dose exercise therapy is not superior to low-dose exercise therapy for knee osteoarthritis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options